PUBLIC COMPANY
save$MAPSWM TECHNOLOGY, INC.
$MAPS0.4170+1.46%Irvine, CA, USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
1
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Flagship brings 3 biotech platforms together to launch AI drug discovery player EtceleraFlagship Pioneering unveiled Etcelera today, a new AI-powered biotech emerging from stealth that aims to predict how potential medicines will act in patients.fiercebiotech · 20d ago
- Opinion: Proposed U.S. census changes could be catastrophic for public health“Erasing data does not erase need or harm,” writes social epidemiologist Nancy Krieger.stat · 1mo ago
- ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plansADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.fiercebiotech · 1mo ago
- Purer fentanyl won’t solve the U.S. overdose death crisis, study saysCautious optimism in the Ebola outbreak, FDA still stymied by DOGE cuts, and other health updates from the Morning Rounds newsletter.stat · 2mo ago
- Opinion: John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill“Nothing in the recent reporting about John Fetterman is medically surprising,” write Michael P.H. Stanley and Isaiah Kletenik.stat · 2mo ago
- Opinion: What STAT readers think about M.D. vs. D.O., AI in medicine, surrogacy, and more“A click, signature, or brief review should not magically transfer responsibility from an AI developer or platform to a physician,” a reader tells STAT.stat · 2mo ago
- Research into protein interactions sheds new light on causes of autismStudying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists at the University of California, San Francisco has suggested.fiercebiotech · 2mo ago
- Pharma marketers need a share-of-answer strategy before AI spendAI is changing how HCPs seek answers. Pharma marketers need a new strategy.biopharma_dive · 2mo ago
- Opinion: STAT readers debate blue zones, open-access publishing fees, and moreKeep those letters coming!stat · 5mo ago
- STAT+: Human Cell Atlas leader’s tie to 10x Genomics raises conflict-of-interest questionsAs the Human Cell Atlas project marks its 10th anniversary, a leader's ties to a major single-cell RNA sequencing company raise conflict-of-interest questions.stat · 5mo ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that